Schrödinger, Inc. (SDGR)

Environment story

Schrödinger discloses no material Scope 1, Scope 2, or Scope 3 emissions data in its 10-K filing. The company operates primarily as a computational drug discovery platform and software vendor, with minimal direct operational footprint. No net-zero target year is disclosed. No evidence of greenwashing via carbon offsets detected. However, the absence of environmental disclosure and targets represents a material gap. The company does report a Bill & Melinda Gates Foundation grant initiative ($19.5M) to develop computational toxicity prediction, which qualifies as a modest verified environmental/scientific investment, though not directly decarbonization infrastructure. No controversies related to environmental compliance, toxic waste, water consumption, or habitat impact are reported in source documents.

Social story

Schrödinger does not disclose CEO-to-median-worker pay ratio, workforce turnover rate, or detailed diversity metrics in the 10-K. The 10-K identifies a May 2025 workforce reduction of ~60 employees (~7% of headcount) and related restructuring costs (~$3M), but provides no evidence of union-suppression activity, strikes, or labor disputes within the past 24 months. No major documented NLRB complaints or union litigation are reported. The company mentions no supply-chain human-rights audits or conflict minerals/lithium/cobalt sourcing disclosures. No diversity percentages (women, underrepresented racial groups) in executive or board leadership are disclosed in the 10-K. The absence of published social metrics and diversity data represents a material disclosure gap relative to modern ESG standards, though no active violations or controversies are evident from the filings.

Governance story

Schrödinger does not disclose board independence percentage, share-structure (single vs. dual-class voting), or lobbying expenditure details in the 10-K filing. The company does not report active antitrust proceedings, consumer-safety litigation, or SEC consent decrees in the provided documents. No evidence of shareholder litigation to block climate/ESG proposals is reported. The company faces typical litigation and IP risks common to biotech (e.g., open-source software indemnification, third-party IP disputes, regulatory compliance) but these are generic risk disclosures not regulatory findings. The absence of explicit governance transparency metrics (board composition, voting structure, lobbying spend) represents a material gap, but no active governance controversies or violations are documented.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Schrödinger, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Schrödinger, Inc. in the app for interactive charts and portfolio building.

More in Technology